Tucatinib with trastuzumab emtansine for treating HER2-positive unresectable or advanced breast cancer after a taxane, trastuzumab or both together [ID6165]
Discontinued
Reference number: GID-TA11318
Following on from advice received from the company, NICE has decided to suspend this appraisal from its work programme whilst the company confirm their regulatory filing plans.
As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes.